Researchers are increasingly investigating retatrutide, a promising treatment created by Eli Lilly, as a potential advance in body loss . Unlike many earlier approaches, retatrutide is a double -action receptor targeting both GLP-1 and GIP, substances that impact satiety and blood sugar regulation .